Valuation: Delcath Systems, Inc.

Market Cap 449M 394M 365M 336M 635M 42.99B 647M 4.35B 1.71B 21.11B 1.69B 1.65B 72.9B P/E 2026 *
-22.9x
P/E 2027 * -24.1x
Enterprise Value 449M 394M 365M 336M 635M 42.99B 647M 4.35B 1.71B 21.11B 1.69B 1.65B 72.9B EV / Sales 2026 *
4.35x
EV / Sales 2027 * 3.44x
Free-Float
91.87%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 2020-09-30
Director of Finance/CFO 47 2023-04-30
Chief Operating Officer 55 2024-03-17
Director TitleAgeSince
Chairman 62 2023-02-15
Director/Board Member 70 2020-02-13
Director/Board Member 60 2020-05-05
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%-2.17%+2.17%-25.85% 20.79B
+1.58%-0.58%-10.31%-12.59% 14.95B
-0.26%-2.93%-60.03%-45.64% 5.53B
-0.20%-7.58% - - 3.67B
+0.95%-1.67%-18.46%-19.08% 1.71B
+0.27%-1.80%+34.43%+12.97% 1.6B
+1.06%+5.16%-39.81%-61.30% 1.19B
+1.30%+6.38%+63.93%+115.38% 824M
-8.81%-14.91% - - 274M
Average -0.46%-1.42%-4.01%-5.16% 5.61B
Weighted average by Cap. +0.65%-1.77%-8.85%-20.77%

Financials

2026 *2027 *
Net sales 103M 90.56M 83.87M 77.17M 146M 9.88B 149M 1B 392M 4.85B 388M 379M 16.76B 131M 115M 106M 97.64M 185M 12.5B 188M 1.26B 496M 6.14B 491M 480M 21.2B
Net income -21.04M -18.46M -17.1M -15.73M -29.75M -2.01B -30.33M -204M -79.91M -989M -79.02M -77.3M -3.42B -20M -17.54M -16.25M -14.95M -28.28M -1.91B -28.83M -194M -75.96M -940M -75.11M -73.47M -3.25B
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-